semaglutide

In a prespecified analysis of the SELECT trial (n=17,604 patients with obesity/overweight and established CVD but without diabetes), once-weekly semaglutide 2.4 mg reduced the composite kidney endpoint by 22% (HR=0.78, 95% CI 0.63-0.96, p=0.02) versus placebo. The endpoint included death from kidney disease, initiation of chronic kidney replacement therapy, persistent eGFR <15 mL/min/1.73m², persistent ≥50% eGFR reduction, or persistent macroalbuminuria. Treatment benefit at 104 weeks for eGFR was +0.75 mL/min/1.73m² overall and +2.19 mL/min/1.73m² in patients with baseline eGFR <60, demonstrating kidney protection independent of weight loss effects.

In the SELECT cardiovascular outcomes trial (n=17,604 adults with preexisting CVD and obesity/overweight without diabetes), semaglutide 2.4 mg once-weekly produced weight loss that continued over 65 weeks and was sustained for up to 4 years. At 208 weeks, semaglutide was associated with mean reductions in weight (−10.2%), waist circumference (−7.7 cm), and waist-to-height ratio (−6.9%) versus placebo (−1.5%, −1.3 cm, −1.0% respectively; all p<0.0001). Clinically meaningful weight loss occurred across all sexes, races, body sizes, and regions. At week 104, 12.0% of semaglutide patients achieved normal weight status (from 0% at baseline) versus 1.2% placebo. Semaglutide was associated with fewer serious adverse events across all BMI categories.

Prespecified analysis of SELECT examining semaglutide 2.4 mg in patients with and without clinical heart failure at baseline (n=4,286 with HF, n=13,318 without). Semaglutide improved all outcome measures in patients with heart failure: MACE reduced 28% (HR=0.72, 95% CI 0.60-0.87), heart failure composite endpoint reduced 21% (HR=0.79, 0.64-0.98), cardiovascular death reduced 24% (HR=0.76, 0.59-0.97), and all-cause death reduced 19% (HR=0.81, 0.66-1.00). Benefits observed in both HFrEF (HR=0.65 for MACE) and HFpEF (HR=0.69 for MACE) with no significant interaction by heart failure subtype. Serious adverse events were less frequent with semaglutide regardless of HF classification.

Using mice expressing genetically encoded cAMP sensors in beta cells, islets were perfused with GLP-1 receptor agonists including semaglutide. While acute GIP treatment induced transient cAMP that dissipated with washout, GLP-1R agonists elicited sustained cAMP responses persisting long after peptide removal—most pronounced with semaglutide and exendin-4. Prolonged cAMP signaling was matched with sustained PKA activity and glucose-stimulated insulin secretion. Exendin(9-39) antagonist treatment failed to return cAMP to baseline, suggesting internalized GLP-1Rs inaccessible to the antagonist continue generating cAMP, explaining the extended pharmacodynamic effects of semaglutide.

Comprehensive review of GLP-1RA effects on gastrointestinal motility. Long-acting agents like semaglutide slow gastric emptying through parasympathetic vagal afferents and direct CNS stimulation. Semaglutide 2.4 mg demonstrated an 8% increase in paracetamol AUC (delayed absorption marker). While tachyphylaxis for gastric emptying effects develops over weeks with sustained exposure, residual slowing persists—for example with semaglutide after 20 weeks of treatment. Mechanisms include inhibition of the migrating motor complex, reduced antral and duodenal pressure waves, and modulation of gastric accommodation. Clinical implications discussed include perioperative aspiration risk and need for adequate fasting periods.

Mechanistic review detailing semaglutide's molecular pathways. GLP-1R binding in pancreatic β-cells activates adenylate cyclase, elevating intracellular cAMP that activates PKA and EPAC2. Two key insulin signaling pathways are engaged: (1) PI3K/PKA/mTOR activates HIF-1, increasing glycolytic gene expression and ATP production for insulin vesicle exocytosis; mTOR-dependent HIF-1 also counteracts DPP-4 degradation. (2) PI3K/AKT promotes GLUT4 translocation to plasma membranes in muscle and adipose for insulin-independent glucose uptake. AMPK/SIRT1 pathway mediates additional glucose transport. Central effects include appetite suppression via hypothalamus/PVN, enhanced thermogenesis, browning of white adipose tissue through UCP1 upregulation, and anti-inflammatory actions.

Landmark double-blind RCT enrolling 17,604 patients ≥45 years with BMI ≥27, established cardiovascular disease, but no diabetes history. Patients received once-weekly subcutaneous semaglutide 2.4 mg or placebo for mean 40-month follow-up. Primary endpoint (composite of CV death, nonfatal MI, or nonfatal stroke) occurred in 6.5% semaglutide vs 8.0% placebo—a 20% reduction (HR=0.80, 95% CI 0.72-0.90, p<0.001). Benefits consistent across sex, ethnicity, age, and baseline BMI. Mean weight loss 9.4% with semaglutide vs 0.9% placebo. Adverse events leading to discontinuation: 16.6% semaglutide (primarily GI symptoms) vs 8.2% placebo. This established semaglutide's cardiovascular benefit independent of diabetes status.

Comprehensive review of the STEP (Semaglutide Treatment Effect in People with obesity) clinical trial program evaluating once-weekly subcutaneous semaglutide 2.4 mg. STEP 1 (n=1,961 adults with obesity, no diabetes): 14.9% weight loss vs 2.4% placebo at 68 weeks. STEP 2 (adults with obesity and type 2 diabetes): 9.6% weight loss. STEP 3 (with intensive behavioral therapy): 16.0% weight loss. STEP 4 (withdrawal study): patients who stopped semaglutide regained 6.9% weight. STEP 5 (2-year extension): sustained 15.2% weight loss. Common adverse events included nausea (44%), diarrhea (30%), and vomiting (24%), typically mild-to-moderate and occurring during dose escalation.

Advanced neural circuit review examining how peripherally administered GLP-1RAs like semaglutide access the CNS. GLP-1RAs primarily target GLP-1R neurons in circumventricular organs (area postrema, median eminence) that lack blood-brain barrier protection, then adjacent regions including nucleus tractus solitarius (NTS) and arcuate nucleus. Critically, the anorectic effects of liraglutide and semaglutide persist following vagal afferent ablation, demonstrating direct central action independent of peripheral vagal signaling. NTS PPG neurons (the primary source of endogenous central GLP-1) are NOT activated by or required for GLP-1RA effects, supporting anatomical and functional separation between peripheral and central GLP-1 systems.